Humana Inc. (NYSE:HUM) Shares Sold by Fifth Third Bancorp

Fifth Third Bancorp lessened its stake in shares of Humana Inc. (NYSE:HUMFree Report) by 37.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 7,194 shares of the insurance provider’s stock after selling 4,368 shares during the period. Fifth Third Bancorp’s holdings in Humana were worth $1,825,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Atlas Brown Inc. increased its holdings in shares of Humana by 0.6% in the 4th quarter. Atlas Brown Inc. now owns 6,352 shares of the insurance provider’s stock valued at $1,611,000 after acquiring an additional 38 shares during the last quarter. Moors & Cabot Inc. increased its stake in Humana by 2.5% in the third quarter. Moors & Cabot Inc. now owns 1,639 shares of the insurance provider’s stock valued at $519,000 after purchasing an additional 40 shares during the last quarter. OLD National Bancorp IN raised its holdings in Humana by 1.8% during the third quarter. OLD National Bancorp IN now owns 2,613 shares of the insurance provider’s stock worth $828,000 after purchasing an additional 45 shares in the last quarter. Your Advocates Ltd. LLP lifted its position in shares of Humana by 81.8% during the 3rd quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares during the last quarter. Finally, Brooklyn Investment Group boosted its holdings in shares of Humana by 6.7% in the 3rd quarter. Brooklyn Investment Group now owns 736 shares of the insurance provider’s stock valued at $233,000 after buying an additional 46 shares in the last quarter. Institutional investors and hedge funds own 92.38% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Leerink Partnrs lowered shares of Humana from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 2nd. Oppenheimer cut their target price on Humana from $400.00 to $280.00 and set an “outperform” rating on the stock in a research report on Thursday, October 3rd. Deutsche Bank Aktiengesellschaft decreased their target price on Humana from $349.00 to $250.00 and set a “hold” rating for the company in a research report on Thursday, October 3rd. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $400.00 to $250.00 in a research report on Wednesday, October 2nd. Finally, Wells Fargo & Company decreased their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Nineteen equities research analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and an average price target of $297.68.

Get Our Latest Report on Humana

Insiders Place Their Bets

In other news, insider Timothy S. Huval sold 3,703 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The stock was sold at an average price of $256.26, for a total transaction of $948,930.78. Following the sale, the insider now owns 8,181 shares of the company’s stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.32% of the stock is currently owned by company insiders.

Humana Trading Up 1.9 %

Shares of HUM stock opened at $303.57 on Wednesday. Humana Inc. has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. The business’s fifty day moving average price is $274.93 and its 200 day moving average price is $303.69. The firm has a market capitalization of $36.55 billion, a PE ratio of 26.89, a P/E/G ratio of 2.15 and a beta of 0.55.

Humana (NYSE:HUMGet Free Report) last posted its quarterly earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, sell-side analysts forecast that Humana Inc. will post 16.11 EPS for the current fiscal year.

Humana Company Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.